|
|

Link:
Pharm/Biotech Resources
Title: Methods and compositions for treating hepatitis B
United States Patent: 6,913,914
Issued: July 5, 2005
Inventors: Cheung; Ling Yuk (Hong Kong, HK)
Assignee: Ultra Biotech Limited (Douglas, GB)
Appl. No.: 717272
Filed: November 18, 2003
Abstract
The invention provides compositions comprising a plurality of yeast
cells, wherein said plurality of yeast cells are characterized by their
ability to normalize the level of serum glutamate-pyruvate Transaminase (GPT),
or reduce serum HBsAg levels in a subject, said ability resulting from their
having been cultured in the presence of an alternating electric field having
a specific frequency and a specific field strength. Also provided are
methods of making and using these compositions.
SUMMARY OF THE INVENTION
This invention is based on the discovery that certain yeast cells can be
activated by electromagnetic fields having specific frequencies and field
strengths to produce substances beneficial for the liver. Compositions
comprising these activated yeast cells can be used as a dietary supplement
or medication for treating liver diseases, e.g., for alleviating or
preventing hepatitis B.
This invention embraces a composition comprising a plurality of yeast cells
that have been cultured in an alternating electric field having a frequency
in the range of about 7900-12400 MHz (e.g., 7900-8100, 9850-10050, or
12200-12400 MHz), and a field intensity in the range of about 240-500 mV/cm
(e.g., 260-280, 270-290, 290-320, 300-330, 310-340, 320-350, 330-360,
360-390, 400-440, or 430-470 mV/cm). The yeast cells are cultured in the
alternating electric field for a period of time sufficient to substantially
increase the capability of said plurality of yeast cells to produce
substances beneficial for the liver (e.g., for treating hepatitis B). In one
embodiment, the frequency and/or the field strength of the alternating
electric field can be altered within the aforementioned ranges during said
period of time. In other words, the yeast cells can be exposed to a series
of electromagnetic fields. An exemplary period of time is about 40-160 hours
(e.g., 60-145 hours).
Also included in this invention is a composition comprising a plurality of
yeast cells that have been cultured under acidic conditions in an
alternating electric field having a frequency in the range of about
9850-12400 MHz (e.g., 12200-12400 MHz) and a field strength in the range of
about 270 to 420 mV/cm (e.g., 300-330 or 360-390 mV/cm). In one embodiment,
the yeast cells are exposed to a series of electromagnetic fields. An
exemplary period of time is about 40-110 hours (e.g., 58-78 hours).
Included in this invention are also methods for making the above
compositions.
Yeast cells that can be included in this composition can be derived from
parent strains publically available from the China General Microbiological
Culture Collection Center ("CGMCC"), China Committee for Culture Collection
of Microorganisms, Institute of Microbiology, Chinese Academy of Sciences,
Haidian, P.O. BOX 2714, Beijing, 100080, China. Useful yeast species
include, but are not limited to Saccharomyces cerevisiae, Saccharomyces
carlsbergensis, Saccharomyces rouxii, Saccharomyces sake, Saccharomyces
uvarum, Saccharomyces sp., Schizosaccharomyces pombe, and
Rhodotorula aurantiaca. For instance, the yeast cells can be of the
strain Saccharomyces cerevisiae Hansen AS2.561 or AS2.69,
Saccharomyces sp. AS2.311, Schizosaccharomyces pombe Lindner
AS2.994, Saccharomyces sake Yabe ACCC2045, Saccharomyces uvarum
Beijer IFFI1044, Saccharomyces rouxii Boutroux AS2.180,
Saccharomyces cerevisiae Hansen Var. ellipsoideus AS2.612,
Saccharomyces carlsbergensis Hansen AS2.377, or Rhodotorula rubar
(Demme) Lodder AS2.282. Other useful yeast strains are illustrated in Table
1.
Unless otherwise defined, all technical and scientific terms used herein
have the same meaning as commonly understood by one of ordinary skill in the
art to which this invention belongs. Exemplary methods and materials are
described below, although methods and materials similar or equivalent to
those described herein can also be used in the practice or testing of the
present invention. All publications and other references mentioned herein
are incorporated by reference in their entirety. In case of conflict, the
present specification, including definitions, will control. The materials,
methods, and examples are illustrative only and not intended to be limiting.
Throughout this specification and claims, the word "comprise," or variations
such as "comprises" or "comprising" will be understood to imply the
inclusion of a stated integer or group of integers but not the exclusion of
any other integer or group of integers.
DETAILED DESCRIPTION OF THE INVENTION
This invention is based on the discovery that certain yeast strains can
be activated by electromagnetic fields ("EMF") having specific frequencies
and field strengths to produce agents useful in treating liver diseases,
e.g., hepatitis B. Yeast compositions containing activated yeast cells can
be used as medication, or as a dietary supplement in the form of health
drinks or dietary pills.
Since the activated yeast cells contained in these yeast compositions have
been cultured to endure acidic conditions (pH 2.5-4.2), the compositions are
stable in the stomach and can pass on to the intestines. Once in the
intestines, the yeast cells are ruptured by various digestive enzymes, and
the bioactive agents are released and readily absorbed.
I. Yeast Strains Useful in the Invention
The types of yeasts useful in this invention include, but are not limited
to, yeasts of the genera of Saccharomyces, Rhodotorula, and
Schizosaccharomyces.
Exemplary species within the above-listed genera include, but are not
limited to, the species illustrated in Table 1. Yeast strains useful in this
invention can be obtained from laboratory cultures, or from publically
accessible culture depositories, such as CGMCC and the American Type Culture
Collection, 10801 University Boulevard, Manassas, Va. 20110-2209.
Non-limiting examples of useful strains (with the accession numbers of CGMCC)
are Saccharomyces cerevisiae Hansen AS2.561 and AS2.69,
Saccharomyces sp. AS2.311, Schizosaccharomyces pombe Lindner
AS2.994, Saccharomyces sake Yabe ACCC2045, Saccharomyces uvarum
Beijer IFFI1044, Saccharomyces rouxii Boutroux AS2.180,
Saccharomyces cerevisiae Hansen Var. ellipsoideus AS2.612,
Saccharomyces carlsbergensis Hansen AS2.377, and Rhodotorula rubar
(Demme) Lodder AS2.282. Other non-limiting examples of useful strains
are listed in Table 1. In general, preferred yeast strains in this invention
are those used for fermentation in the food and wine industries. As a
result, compositions containing these yeast cells are safe for human
consumption.
The preparation of the yeast compositions of this invention is not limited
to starting with a pure strain of yeast. A yeast composition of the
invention may be produced by culturing a mixture of yeast cells of different
species or strains.
| TABLE 1 |
| Exemplary Yeast Strains |
| Saccharomyces cerevisiae Hansen |
| ACCC2034 |
ACCC2035 |
ACCC2036 |
ACCC2037 |
ACCC2038 |
| ACCC2039 |
ACCC2040 |
ACCC2041 |
ACCC2042 |
AS2. 1 |
| AS2.4 |
AS2.11 |
AS2.14 |
AS2.16 |
AS2.56 |
| AS2.69 |
AS2.70 |
AS2.93 |
AS2.98 |
AS2.101 |
| AS2.109 |
AS2.110 |
AS2.112 |
AS2.139 |
AS2.173 |
| AS2.174 |
AS2.182 |
AS2.196 |
AS2.242 |
AS2.336 |
| AS2.346 |
AS2.369 |
AS2.374 |
AS2.375 |
AS2.379 |
| AS2.380 |
AS2.382 |
AS2.390 |
AS2.393 |
AS2.395 |
| AS2.396 |
AS2.397 |
AS2.398 |
AS2.399 |
AS2.400 |
| AS2.406 |
AS2.408 |
AS2.409 |
AS2.413 |
AS2.414 |
| AS2.415 |
AS2.416 |
AS2.422 |
AS2.423 |
AS2.430 |
| AS2.431 |
AS2.432 |
AS2.451 |
AS2.452 |
AS2.453 |
| AS2.458 |
AS2.460 |
AS2.463 |
AS2.467 |
AS2.486 |
| AS2.501 |
AS2.502 |
AS2.503 |
AS2.504 |
AS2.516 |
| AS2.535 |
AS2.536 |
AS2.558 |
AS2.560 |
AS2.561 |
| AS2.562 |
AS2.576 |
AS2.593 |
AS2.594 |
AS2.614 |
| AS2.620 |
AS2.628 |
AS2.631 |
AS2.666 |
AS2.982 |
| AS2.1190 |
AS2.1364 |
AS2. 1396 |
IFFI1001 |
IFFI1002 |
| IFFI1005 |
IFFI1006 |
IFFI1008 |
IFFI1009 |
IFFI1010 |
| IFFI1012 |
IFFI1021 |
IFFI1027 |
IFFI1037 |
IFFI1042 |
| IFFI1043 |
IFFI1045 |
IFFI1048 |
IFFI1049 |
IFFI1050 |
| IFFI1052 |
IFFI1059 |
IFFI1060 |
IFFI1062 |
IFFI1063 |
| IFFI1202 |
IFFI1203 |
IFFI1206 |
IFFI1209 |
IFFI1210 |
| IFFI1211 |
IFFI1212 |
IFFI1213 |
IFFI1214 |
IFFI1215 |
| IFFI1220 |
IFFI1221 |
IFFI1224 |
IFFI1247 |
IFFI1248 |
| IFFI1251 |
IFFI1270 |
IFFI1277 |
IFFI1287 |
IFFI1289 |
| IFFI1290 |
IFFI1291 |
IFFI1292 |
IFFI1293 |
IFFI1297 |
| IFFI1300 |
IFFI1301 |
IFFI1302 |
IFFI1307 |
IFFI1308 |
| IFFI1309 |
IFFI1310 |
IFFI1311 |
IFFI1331 |
IFFI1335 |
| IFFI1336 |
IFFI1337 |
IFFI1338 |
IFFI1339 |
IFFI1340 |
| IFFI1345 |
IFFI1348 |
IFFI1396 |
IFFI1397 |
IFFI1399 |
| IFFI1411 |
IFFI1413 |
IFFI1441 |
IFFI1443 |
Saccharomyces cerevisiae Hansen Var. ellipsoideus (Hansen)
Dekker |
| ACCC2043 |
AS2.2 |
AS2.3 |
AS2.8 |
AS2.53 |
| AS2.163 |
AS2.168 |
AS2.483 |
AS2.541 |
AS2.559 |
| AS2.606 |
AS2.607 |
AS2.611 |
AS2.612 |
| Saccharomyces chevalieri Guilliermond |
| Saccharomyces delbrueckii |
| Saccharomyces delbrueckii |
| Lindner ver. mongolicus (Saito) Lodder et van Rij |
| Saccharomyces exiguous Hansen |
| Saccharomyces fermentaii (Saito) Lodder et van Rij |
| Saccharomyces logos van laer et Denamur ex Jorgensen |
| Saccharomyces mellis (Fabian et Quinet) Lodder et kreger
van Rij |
| Saccharomyces mellis Microellipsoides Osterwalder |
| Saccharomyces oviformis Osteralder |
| Saccharomyces rosei (Guilliermond) Lodder et Kreger van Rij |
| Saccharomyces rouxii Boutroux |
| AS2.178 |
AS2.180 |
AS2.370 |
AS2.371 |
|
| Candida lambica (Lindner et Genoud) van. Uden et Buckley |
| Candida krusei (Castellani) Berkhout |
| Candida lipolytica (Harrison) Diddens et Lodder |
| AS2.1207 |
AS2.1216 |
AS2.1220 |
AS2.1379 |
AS2.1398 |
| AS2.1399 |
AS2.1400 |
| Candida parapsilosis (Ashford) Langeron et Talice Var.
intermedia |
| Van Rij et Verona |
| Candida parapsilosis (Ashford) Langeron et Talice |
| Candida pulcherrima (Lindner) Windisch |
| Candida rugousa (Anderson) Diddens et Lodder |
| AS2.511 |
AS2.1367 |
AS2.1369 |
AS2.1372 |
AS2.1373 |
| AS2.1377 |
AS2.1378 |
AS2.1384 |
| Candida tropicalis (Castellani) Berkhout |
| ACCC2004 |
ACCC2005 |
ACCC2006 |
AS2.164 |
AS2.402 |
| AS2.564 |
AS2.565 |
AS2.567 |
AS2.568 |
AS2.617 |
| AS2.637 |
AS2.1387 |
AS2.1397 |
| Candida utilis Henneberg Lodder et Kreger Van Rij |
| Crebrothecium ashbyii (Guillermond) |
| Routein (Eremothecium ashbyii Guilliermond) |
| ACCC2016 |
AS2.361 |
AS2.498 |
AS2.616 |
AS2.1035 |
| AS2.1062 |
AS2.1080 |
AS2.1132 |
AS2.1175 |
AS2.1183 |
| Hansenula anomala (Hansen)H et P sydow |
| ACCC2018 |
AS2.294 |
AS2.295 |
AS2.296 |
AS2.297 |
| AS2.298 |
AS2.299 |
AS2.300 |
AS2.302 |
AS2.338 |
| AS2.339 |
AS2.340 |
AS2.341 |
AS2.470 |
AS2.592 |
| AS2.641 |
AS2.642 |
AS2.782 |
AS2.635 |
AS2.794 |
| Hansenula arabitolgens Fang |
| Hansenula jadinii (A. et R Sartory Weill et Meyer)
Wickerham |
| Hansenula saturnus (Klocker) H et P sydow |
| Hansenula schneggii (Weber) Dekker |
| Hansenula subpelliculosa Bedford |
| AS2.740 |
AS2.760 |
AS2.761 |
AS2.770 |
AS2.783 |
| A52.790 |
AS2.798 |
AS2.866 |
| Kloeckera apiculata (Reess emend. Klocker) Janke |
| ACCC2022 |
ACCC2023 |
AS2.197 |
AS2.496 |
AS2.714 |
| ACCC2021 |
AS2.711 |
| Lipomycess starkeyi Lodder et van Rij |
| Pichia farinosa (Lindner) Hansen |
| ACCC2025 |
ACCC2026 |
AS2.86 |
AS2.87 |
AS2.705 |
| AS2.803 |
| Pichia membranaefaciens Hansen |
| ACCC2027 |
AS2.89 |
AS2.661 |
AS2.1039 |
|
| Rhodosporidium toruloides Banno |
| Rhodotorula glutinis (Fresenius) Harrison |
| AS2.2029 |
AS2.280 |
ACCC2030 |
AS2.102 |
AS2.107 |
| AS2.278 |
AS2.499 |
AS2.694 |
AS2.703 |
AS2.704 |
| AS2.1146 |
| Rhodotorula minuta (Saito) Harrison |
| Rhodotorula rubar (Demme) Lodder |
| AS2.21 |
AS2.22 |
AS2.103 |
AS2.105 |
AS2.108 |
| AS2.140 |
AS2.166 |
AS2.167 |
AS2.272 |
AS2.279 |
| AS2.282 |
ACCC2031 |
| Rhodotorula aurantiaca (Saito) Lodder |
| AS2.102 |
AS2.107 |
AS2.278 |
AS2.499 |
AS2.694 |
| AS2.703 |
AS2.1146 |
| Saccharomyces carlsbergensis Hansen |
| AS2.113 |
ACCC2032 |
ACCC2033 |
AS2.312 |
AS2.116 |
| AS2.118 |
AS2.121 |
AS2.132 |
AS2.162 |
AS2.189 |
| Saccharomyces uvarum Beijer |
| IFFI1023 |
IFFI1032 |
IFFI1036 |
IFFI1044 |
IFFI1072 |
| IFFI1205 |
IFFI1207 |
| Saccharomyces willianus Saccardo |
| AS2.5 |
AS2.7 |
AS2.119 |
AS2.152 |
AS2.293 |
| AS2.381 |
AS2.392 |
AS2.434 |
AS2.614 |
AS2.1189 |
| Saccharomycodes ludwigii Hansen |
| Saccharomycodes sinenses Yue |
| Schizosaccharomyces octosporus Beijerinck |
| Schizosaccharomyces pombe Lindner |
| ACCC2047 |
ACCC2048 |
AS2.214 |
AS2.248 |
AS2.249 |
| AS2.255 |
AS2.257 |
AS2.259 |
AS2.260 |
AS2.274 |
| AS2.994 |
AS2.1043 |
AS2.1149 |
AS2.1178 |
IFFI1056 |
| Sporobolomyces roseus Kluyver et van Niel |
| ACCC2049 |
ACCC2050 |
AS2.19 |
AS2.962 |
AS2.1036 |
| ACCC2051 |
AS2.261 |
AS2.262 |
| Torulopsis candida (Saito) Lodder |
| Torulopsis famta (Harrison) Lodder et van Rij |
| Torulopsis globosa (Olson et Hammer) Lodder et van Rij |
| Torulopsis inconspicua Lodder et Kreger van Rij |
| Trichosporon behrendii Lodder et Kreger van Rij |
| Trichosporon capitatum Diddens et Lodder |
| Trichosporon cutaneum (de Reurm et al.) Ota |
| ACCC2057 |
AS2.25 |
AS2.570 |
AS2.571 |
AS2.1374 |
| Wickerhamia fluorescens (Soneda) Soneda |
II. Application of Electromagnetic Fields
An electromagnetic field useful in this invention can be generated and
applied by various means well known in the art. For instance, the EMF can be
generated by applying an alternating electric field or an oscillating
magnetic field.
Alternating electric fields can be applied to cell cultures through
electrodes in direct contact with the culture medium, or through
electromagnetic induction. See, e.g., FIG. 1. Relatively high
electric fields in the medium can be generated using a method in which the
electrodes are in contact with the medium. Care must be taken to prevent
electrolysis at the electrodes from introducing undesired ions into the
culture and to prevent contact resistance, bubbles, or other features of
electrolysis from dropping the field level below that intended. Electrodes
should be matched to their environment, for example, using Ag-AgCl
electrodes in solutions rich in chloride ions, and run at as low a voltage
as possible. For general review, see Goodman et al., Effects of EMF on
Molecules and Cells, International Review of Cytology, A Survey of Cell
Biology, Vol. 158, Academic Press, 1995.
The EMFs useful in this invention can also be generated by applying an
oscillating magnetic field. An oscillating magnetic field can be generated
by oscillating electric currents going through Helmholtz coils. Such a
magnetic field in turn induces an electric field.
The frequencies of EMFs useful in this invention range from about 7900 MHz
to 12400 MHz (e.g., 7900-8100, 9850-10050, or 12200-12400 MHz). Exemplary
frequencies include 7986, 8009, 9949, 12293, and 12312 MHz. The field
strength of the electric field useful in this invention ranges from about
240-500 mV/cm (e.g., 260-280, 270-290, 290-320, 300-330, 310-340, 320-350,
330-360, 360-390, 400-440, or 430-470 mV/cm). Exemplary field strengths
include 267, 272, 285, 298, 315, 317, 327, 337, 347, 375, 416, and 446
mV/cm.
When a series of EMFs are applied to a yeast culture, the yeast culture can
remain in the same container while the same set of EMF generator and
emitters is used to change the frequency and/or field strength. The EMFs in
the series can each have a different frequency or a different field
strength; or a different frequency and a different field strength. Such
frequencies and field strengths are preferably within the above-described
ranges. Although any practical number of EMFs can be used in a series, it
may be preferred that the yeast culture be exposed to a total of 2, 3, 4, 5,
6, 7, 8, 9, 10, 11, 12, 13, or more EMFs in a series. In one embodiment, the
yeast culture is exposed to a series of EMFs, wherein the frequency of the
electric field is alternated in the range of about 7900-8100, 9850-10050,
and 12200-12400 MHz.
Although the yeast cells can be activated after even a few hours of
culturing in the presence of an EMF, it may be preferred that the activated
yeast cells be allowed to multiply and grow in the presence of the EMF(s)
for a total of 40-160 hours.
FIG. 1 illustrates an exemplary apparatus for generating alternating
electric fields (see original patent).
III. Culture Media
Culture media useful in this invention contain sources of nutrients that can
be assimilated by yeast cells. Complex carbon-containing substances in a
suitable form (e.g., carbohydrates such as sucrose, glucose, dextrose,
maltose, xylose, cellulose, starch, etc.) can be the carbon sources for
yeast cells. The exact quantity of the carbon sources can be adjusted in
accordance with the other ingredients of the medium. In general, the amount
of carbohydrates varies between about 1% and 10% by weight of the medium and
preferably between about 1% and 5%, and most preferably about 2%. These
carbon sources can be used individually or in combination. Amino
acid-containing substances such as beef extract and peptone can also be
added. In general, the amount of amino acid containing substances varies
between about 0.1% and 1% by weight of the medium and preferably between
about 0.1% and 0.5%. Among the inorganic salts which can be added to a
culture medium are the customary salts capable of yielding sodium,
potassium, calcium, phosphate, sulfate, carbonate, and like ions.
Non-limiting examples of nutrient inorganic salts are (NH4)2HPO4,
CaCO3, KH2PO4, K2 HPO4,
MgSO4, NaCl, and CaSO4.
IV. Electromagnetic Activation of Yeast Cells
To activate or enhance the ability of yeast cells to produce agents useful
for treating live diseases (e.g., hepatitis B), these cells can be cultured
in an appropriate medium under sterile conditions at 20-35° C. (e.g., 28-32°
C.) for a sufficient amount of time (e.g., 60-145 hours) in an alternating
electric field or a series of alternating electric fields as described
above.
An exemplary set-up of the culture process is depicted in FIG. 1 (see
above). An exemplary culture medium contains the following per 1000 ml of
sterile water: 18 g of mannitol, 50 μg of Vitamin B6, 50 μg of
Vitamin B12, 50 μg of Vitamin B3, 100 □g of Vitamin H,
35 ml of fetal bovine serum, 0.2 g of KH2PO4, 0.25 g
of MgSO4.7H2O, 0.3 g of NaCl, 0.2 g of CaSO4.2H2O,
4 g of CaCO3.5H2O, and 2.5 g of peptone. Yeast cells
of the desired strain(s) are then added to the culture medium to form a
mixture containing 1×108 cells per 1000 ml of culture medium. The
yeast cells can be of any of the strains listed in Table 1. The mixture is
then added to the apparatus shown in FIG. 1 (see original patent).
The activation process of the yeast cells involves the following steps: (1)
maintaining the temperature of the activation apparatus at 24-33° C. (e.g.,
28-32° C.), and culturing the yeast cells for 24-30 hours (e.g., 28 hours);
(2) applying an alternating electric field having a frequency of 7986 MHz
and a field strength of 260-280 mV/cm (e.g., 267 mV/cm) for 11-17 hours
(e.g., 15 hours); (3) then applying an alternating electric field having a
frequency of 8009 MHz and a field strength of 310-340 mV/cm (e.g., 315
mV/cm) for 32-38 hours (e.g., 36 hours); (4) then applying an alternating
electric field having a frequency of 9949 MHz and a field strength of
320-350 mV/cm (e.g., 337 mV/cm) for 38-44 hours (e.g., 42 hours); (5) then
applying an alternating electric field having a frequency of 12293 MHz and a
field strength of 330-360 mV/cm (e.g., 347 mV/cm) for 35-41 hours (e.g., 39
hours); and (6) then applying an alternating electric field having a
frequency of 12312 MHz and a field strength of 260-280 mV/cm (e.g., 272
mV/cm) for 6-12 hours (e.g., 10 hours). The activated yeast cells are then
recovered from the culture medium by various methods known in the art, dried
(e.g., by lyophilization) and stored at 4° C. Preferably, the concentration
of the dried yeast cells is no less than 1010 cells/g.
V. Acclimatization of Yeast Cells to the Gastric Environment
Because the yeast compositions of this invention must pass through the
stomach before reaching the small intestine, where the effective components
are released from these yeast cells, it is preferred that these yeast cells
be cultured under acidic conditions to acclimatize the cells to the gastric
juice. This acclimatization process results in better viability of the yeast
cells in the acidic gastric environment.
To achieve this, the yeast powder containing activated yeast cells can be
mixed with a highly acidic acclimatizing culture medium at 10 g (containing
more than 1010 activated cells per gram) per 1000 ml. The yeast
mixture is then cultured first in the presence of an alternating electric
field having a frequency of 12293 MHz and a field strength of 360-390 mV/cm
(e.g., 375 mV/cm) at about 28 to 32° C. for 42 to 50 hours (e.g., 46 hours).
The resultant yeast cells can then be further incubated in the presence of
an alternating electric field having a frequency of 12312 MHz and a field
strength of 300-330 mV/cm (e.g., 317 mV/cm) at about 28 to 32° C. for 16 to
28 hours (e.g., 20 hours). The resulting acclimatized yeast cells are then
dried and stored either in powder form (≧1010 cells/g) at room
temperature or in vacuum at 0-4° C.
An exemplary acclimatizing culture medium is made by mixing 700 ml fresh pig
gastric juice and 300 ml wild Chinese hawthorn extract. The pH of the
acclimatizing culture medium is adjusted to 2.5 with 0.1 M hydrochloric acid
(HCl) and 0.2 M potassium hydrogen phthalate (C6H4(COOK)COOH).
The fresh pig gastric juice is prepared as follows. At about 4 months of
age, newborn Holland white pigs are sacrificed, and the entire contents of
their stomachs are retrieved and mixed with 2000 ml of water under sterile
conditions. The mixture is then allowed to stand for 6 hours at 4° C. under
sterile conditions to precipitate food debris. The supernatant is collected
for use in the acclimatizing culture medium. To prepare the wild Chinese
hawthorn extract, 500 g of fresh wild Chinese hawthorn is dried under
sterile conditions to reduce water content (≦8%). The dried fruit is then
ground (≧20 mesh) and added to 1500 ml of sterilized water. The hawthorn
slurry is allowed to stand for 6 hours at 4° C. under sterile conditions.
The hawthorn supernatant is collected to be used in the acclimatizing
culture medium.
VI. Manufacture of Yeast Compositions
To manufacture the yeast compositions of the invention, an apparatus
depicted in FIG. 2 or an equivalent thereof can be used. This apparatus
includes three containers, a first container (A), a second container (B),
and a third container (C), each equipped with a pair of electrodes (4).
One of the electrodes is a metal plate placed on the bottom of the
containers, and the other electrode comprises a plurality of electrode wires
evenly distributed in the space within the container to achieve even
distribution of the electric field energy. All three pairs of electrodes are
connected to a common signal generator.
The culture medium used for this purpose is a mixed fruit extract solution
containing the following ingredients per 1000 L: 300 L of wild Chinese
hawthorn extract, 300 L of jujube extract, 300 L of Schisandra chinensis
(Turez) Baill seed extract, and 100 L of soy bean extract. To prepare
hawthorn, jujube and Schisandra chinensis (Turez) Baill seed
extracts, the fresh fruits are washed and dried under sterile conditions to
reduce the water content to no higher than 8%. One hundred kilograms of the
dried fruits are then ground (≧20 mesh) and added to 400 L of sterilized
water. The mixtures are stirred under sterile conditions at room temperature
for twelve hours, and then centrifuged at 1000 rpm to remove insoluble
residues. To make the soy bean extract, fresh soy beans are washed and dried
under sterile conditions to reduce the water content to no higher than 8%.
Thirty kilograms of dried soy beans are then ground into particles of no
smaller than 20 mesh, and added to 130 L of sterilized water. The mixture is
stirred under sterile conditions at room temperature for twelve hours and
centrifuged at 1000 rpm to remove insoluble residues. To make the culture
medium, these ingredients are mixed according to the above recipe, and the
mixture is autoclaved at 121° C. for 30 minutes and cooled to below 40° C.
before use.
One thousand grams of the activated yeast powder prepared as described above
(Section V, supra) is added to 1000 L of the mixed fruit extract solution,
and the yeast solution is transferred to the first container (A) shown in
FIG. 2. The yeast cells are then cultured in the presence of an
alternating electric field having a frequency of 12293 MHz and a field
strength of about 400-440 mV/cm (e.g., 416 mV/cm) at 28-32° C. under sterile
conditions for 32 hours. The yeast cells are further incubated in an
alternating electric field having a frequency of 12312 MHz and a field
strength of 290-320 mV/cm (e.g., 298 mV/cm). The culturing continues for
another 12 hours.
The yeast culture is then transferred from the first container (A) to the
second container (B) which contains 1000 L of culture medium (if need be, a
new batch of yeast culture can be started in the now available first
container (A)), and subjected to an alternating electric field having a
frequency of 12293 MHz and a field strength of 430-470 mV/cm (e.g., 446
mV/cm) for 24 hours. Subsequently the frequency and field strength of the
electric field are changed to 12312 MHz and 260-280 mV/cm (e.g., 272 mV/cm),
respectively. The culturing continues for another 12 hours.
The yeast culture is then transferred from the second container (B) to the
third container (C) which contains 1000 L of culture medium, and subjected
to an alternating electric field having a frequency of 12293 MHz and a field
strength of 310-340 mV/cm (e.g., 327 mV/cm) for 24 hours. Subsequently the
frequency and field strength of the electric field are changed to 12312 MHz
and 270-290 mV/cm (e.g., 285 mV/cm), respectively. The culturing continues
for another 12 hours.
The yeast culture from the third container (C) can then be packaged into
vacuum sealed bottles for use as a dietary supplement, e.g., health drinks,
or medication in the form of pills, powder, etc. If desired, the final yeast
culture can also be dried within 24 hours and stored in powder form. The
dietary supplement can be taken three to four times daily at 30-60 ml per
dose for a three-month period, preferably 10-30 minutes before meals and at
bedtime.
In some embodiments, the compositions of the invention can also be
administered intravenously or peritoneally in the form of a sterile
injectable preparation. Such a sterile preparation can be prepared as
follows. A sterilized health drink composition is first treated under
ultrasound (20,000 Hz) for 10 minutes and then centrifuged for another 10
minutes. The resulting supernatant is adjusted to pH 7.2-7.4 using 1 M NaOH
and subsequently filtered through a membrane (0.22 μm for intravenous
injection and 0.45 μM for peritoneal injection) under sterile conditions.
The resulting sterile preparation is submerged in a 35-38° C. water bath for
30 minutes before use. In other embodiments, the compositions of the
invention may also be formulated with pharmaceutically acceptable carriers
to be orally administered in any orally acceptable dosage form including,
but not limited to, capsules, tablets, suspensions or solutions.
The yeast compositions of the present invention are derived from yeasts used
in food and pharmaceutical industries. The yeast compositions are thus
devoid of side effects associated with many pharmaceutical compounds.
Claim 1 of 10 Claims
1. A composition comprising a plurality of yeast cells, wherein said
plurality of yeast cells are characterized by their ability to normalize
the level of serum glutamate-pyruvate Transaminase (GPT), or reduce serum
HBsAg levels in a subject, said ability resulting from their having been
cultured in the presence of an alternating electric field having a
frequency in the range of 7900-12400 MHz and a field strength in the range
of 240-500 mV/cm, as compared to yeast cells not having been so cultured.
____________________________________________
If you want to learn more
about this patent, please go directly to the U.S.
Patent and Trademark Office Web site to access the full
patent.
|